Karyopharm Therapeutics Inc. (NASDAQ: KPTI) entered into a securities purchase agreement with RA Capital Management for a private placement expected to generate approximately $30 million in gross proceeds before fees and expenses.

The Newton, Massachusetts-based pharmaceutical company will sell 1,030,354 shares of common stock at $6.785 per share and 3,391,164 pre-funded warrants at $6.7849 each. The transaction includes accompanying warrants to purchase 4,421,518 shares at an exercise price of $10.00 per share.

The pre-funded warrants carry an exercise price of $0.0001 per share, are immediately exercisable and do not expire. The accompanying warrants are also immediately exercisable but will expire 30 days after the company announces topline results from its Phase 3 XPORT-EC-042 clinical trial of selinexor in endometrial cancer patients.

If all accompanying warrants are exercised, the company would receive an additional $44 million in gross proceeds. The private placement is expected to close on or about March 26, 2026, subject to customary closing conditions.

Karyopharm stated that the net proceeds from the placement, combined with existing liquidity and cash flow from product revenue, will fund current operating plans into late third quarter 2026. The company plans to use proceeds for general corporate purposes, including clinical trial activities.

Jefferies and Piper Sandler served as placement agents for the transaction. The securities are being sold under an exemption from Securities Act registration requirements.

Karyopharm markets XPOVIO, an oral exportin 1 inhibitor approved for three oncology indications in the United States and various indications in 50 territories outside the U.S.